Replies to post #65518 on Anavex Life Sciences Corp (AVXL)

[JB3729]

Why would you state this -

"Hence the Part A dose dependency title as a placeholder."


When the AAIC states this -

"If you are interested in having the research you present at AAIC eligible for inclusion in AAIC news releases and news conferences, it must not be published (online or hard copy) or presented, in whole or in part, in any manner, previous to the presentation at AAIC."

[circa1762]

Part B does measure dose dependency -- there is a 30mg arm and a 50mg arm. Company has apparently found, as per the poster title, that patients in the 50mg arm have as a group improved MMSE score (and other cognitive measures) to a greater degree than patients in the 30mg arm.